-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59

Benzinga·10/05/2026 13:06:05
Leerink Partners analyst David Risinger downgrades Bristol-Myers Squibb (NYSE:BMY) from Outperform to Market Perform and lowers the price target from $73 to $59.